EICHOR
● Recruiting
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
Condition: Early Breast Cancer · Premenopausal Breast Cancer · HR+/HER2- Breast Cancer · Sponsor: UNICANCER
About this study
Rationale: Around 70 to 80% of breast cancers are so-called "hormone-dependent" (HR+)/HER2-. For more than 50 years, studies have shown that chemotherapy and optimised hormonal treatments (hormone therapy), including a drug associated with ovarian suppression (OFS), improve survival in patients with these cancers, which are characterised by a high risk of relapse. However, younger patients suffer more side effects than older women, particularly from chemotherapy. This can affect their quality of life and reduce their ability to work. For post-menopausal women, genetic tests exist to assess whether chemotherapy is really necessary in addition to hormonal treatment. However, for high-risk premenopausal patients, chemotherapy is still systematically recommended, as no study has proved that it can be safely avoided. Clinical trials based on risk stratification using genetic tests have not been conclusive, but the majority of premenopausal women included had not received optimal hormone treatment. It is possible that the beneficial effect of chemotherapy is partly due to the artificial menopause it induces. Some experts believe that, for patients with a high clinical risk but a low genetic risk, an optimised hormonal treatment (drug + OFS) could suffice, without the need for chemotherapy. Objectives: Main objective: The aim of the study is to determine whether the use of a genetic test (Prosigna®) to decide whether or not to administer chemotherapy produces results as good as …
This description comes directly from the study's public registry record.
Talk to the study team
Aure Vanhecke · +33662962532 · a-vanhecke@unicancer.fr
Vanhecke
Always discuss trial participation with your own doctor first.
Locations (105)
| Institut Jules Bordet | Brussels, Belgium | Not Yet Recruiting |
| Cliniques Universitaires Saint-Luc | Brussels, Belgium | Not Yet Recruiting |
| Grand Hôpital de Charleroi | Charleroi, Belgium | Not Yet Recruiting |
| CHU Helora Hôpital de La Louvière - Site Jolimont | Haine-Saint-Paul, Belgium | Not Yet Recruiting |
| CHU UCL Namur - Site Sainte Elisabeth | Namur, Belgium | Not Yet Recruiting |
| Clinique Saint Pierre | Ottignies, Belgium | Not Yet Recruiting |
| CHR Verviers | Verviers, Belgium | Not Yet Recruiting |
| Centre Hospitalier d'Auxerre | Auxerre, France | Recruiting |
| Sainte Catherine - Institut du Cancer Avignon-Provence | Avignon, France | Recruiting |
| Centre Hospitalier de la Côte Basque | Bayonne, France | Not Yet Recruiting |
| Centre Hospitalier Simone Veil de Beauvais | Beauvais, France | Recruiting |
| Hôpital de Blois | Blois, France | Not Yet Recruiting |
+ 93 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.